BPI-16350
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer. It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.
BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer. It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329434894 under CC BY-SA 4.0; modifications have been made.